2020 Q2 Form 10-Q Financial Statement
#000156459020037775 Filed on August 06, 2020
Income Statement
| Concept | 2020 Q2 | 2019 Q2 | 2019 Q1 |
|---|---|---|---|
| Revenue | $16.57M | $7.881M | $884.0K |
| YoY Change | 110.2% | -80.31% | -99.33% |
| Cost Of Revenue | $4.700M | $1.900M | $29.00K |
| YoY Change | 147.37% | -51.28% | -98.8% |
| Gross Profit | $11.90M | $6.000M | $855.0K |
| YoY Change | 98.33% | -83.43% | -99.34% |
| Gross Profit Margin | 71.83% | 76.13% | 96.72% |
| Selling, General & Admin | $15.60M | $13.40M | $11.60M |
| YoY Change | 16.42% | 61.45% | 38.1% |
| % of Gross Profit | 131.09% | 223.33% | 1356.73% |
| Research & Development | $38.11M | $29.48M | $25.20M |
| YoY Change | 29.26% | 37.22% | 28.92% |
| % of Gross Profit | 320.26% | 491.38% | 2947.72% |
| Depreciation & Amortization | $2.100M | $1.800M | $1.600M |
| YoY Change | 16.67% | 100.0% | 100.0% |
| % of Gross Profit | 17.65% | 30.0% | 187.13% |
| Operating Expenses | $38.11M | $29.48M | $25.20M |
| YoY Change | 29.26% | 37.22% | 28.92% |
| Operating Profit | -$26.21M | -$23.48M | -$35.91M |
| YoY Change | 11.62% | -469.81% | -135.19% |
| Interest Expense | $7.600M | $35.30M | $3.600M |
| YoY Change | -78.47% | 335.8% | 63.64% |
| % of Operating Profit | |||
| Other Income/Expense, Net | $3.608M | ||
| YoY Change | 62.96% | ||
| Pretax Income | -$34.30M | -$1.600M | -$32.30M |
| YoY Change | 2043.75% | -111.11% | -130.98% |
| Income Tax | -$500.0K | -$100.0K | $70.00K |
| % Of Pretax Income | |||
| Net Earnings | -$33.76M | -$1.457M | -$32.23M |
| YoY Change | 2217.23% | -113.75% | -130.92% |
| Net Earnings / Revenue | -203.8% | -18.49% | -3645.7% |
| Basic Earnings Per Share | -$0.91 | -$0.04 | -$0.89 |
| Diluted Earnings Per Share | -$0.91 | -$0.04 | -$0.89 |
| COMMON SHARES | |||
| Basic Shares Outstanding | 36.67M | 36.37M | |
| Diluted Shares Outstanding | 36.67M | 36.37M |
Balance Sheet
| Concept | 2020 Q2 | 2019 Q2 | 2019 Q1 |
|---|---|---|---|
| SHORT-TERM ASSETS | |||
| Cash & Short-Term Investments | $269.2M | $341.5M | $285.2M |
| YoY Change | -21.17% | 19.2% | 24.05% |
| Cash & Equivalents | $94.22M | $55.14M | $55.85M |
| Short-Term Investments | $175.0M | $286.4M | $229.4M |
| Other Short-Term Assets | $17.00M | $8.300M | $10.30M |
| YoY Change | 104.82% | 38.33% | 49.28% |
| Inventory | |||
| Prepaid Expenses | |||
| Receivables | $42.90M | $9.700M | $8.400M |
| Other Receivables | $0.00 | $0.00 | $0.00 |
| Total Short-Term Assets | $329.1M | $359.5M | $303.9M |
| YoY Change | -8.46% | 22.57% | 15.68% |
| LONG-TERM ASSETS | |||
| Property, Plant & Equipment | $32.70M | $27.33M | $23.14M |
| YoY Change | 19.63% | 63.65% | 56.35% |
| Goodwill | |||
| YoY Change | |||
| Intangibles | |||
| YoY Change | |||
| Long-Term Investments | $70.10M | $108.2M | $159.1M |
| YoY Change | -35.21% | 446.46% | 2596.61% |
| Other Assets | $5.700M | $4.300M | $3.300M |
| YoY Change | 32.56% | 152.94% | 200.0% |
| Total Long-Term Assets | $120.6M | $169.6M | $215.1M |
| YoY Change | -28.89% | 297.19% | 294.68% |
| TOTAL ASSETS | |||
| Total Short-Term Assets | $329.1M | $359.5M | $303.9M |
| Total Long-Term Assets | $120.6M | $169.6M | $215.1M |
| Total Assets | $449.7M | $529.1M | $519.0M |
| YoY Change | -15.01% | 57.47% | 63.62% |
| SHORT-TERM LIABILITIES | |||
| YoY Change | |||
| Accounts Payable | $10.90M | $5.900M | $4.200M |
| YoY Change | 84.75% | 40.48% | -16.0% |
| Accrued Expenses | $28.90M | $18.20M | $15.50M |
| YoY Change | 58.79% | 89.58% | 56.57% |
| Deferred Revenue | $600.0K | ||
| YoY Change | |||
| Short-Term Debt | $0.00 | $0.00 | $0.00 |
| YoY Change | |||
| Long-Term Debt Due | |||
| YoY Change | |||
| Total Short-Term Liabilities | $40.20M | $24.70M | $21.40M |
| YoY Change | 62.75% | 46.15% | 43.62% |
| LONG-TERM LIABILITIES | |||
| Long-Term Debt | $0.00 | $0.00 | $0.00 |
| YoY Change | |||
| Other Long-Term Liabilities | $11.70M | $1.900M | $1.772M |
| YoY Change | 515.79% | 163.89% | -0.23% |
| Total Long-Term Liabilities | $11.70M | $1.900M | $1.772M |
| YoY Change | 515.79% | 163.89% | -0.23% |
| TOTAL LIABILITIES | |||
| Total Short-Term Liabilities | $40.20M | $24.70M | $21.40M |
| Total Long-Term Liabilities | $11.70M | $1.900M | $1.772M |
| Total Liabilities | $51.90M | $34.50M | $31.98M |
| YoY Change | 50.43% | 83.51% | 78.65% |
| SHAREHOLDERS EQUITY | |||
| Retained Earnings | -$251.6M | -$116.8M | -$115.3M |
| YoY Change | 115.41% | ||
| Common Stock | $602.4M | ||
| YoY Change | |||
| Preferred Stock | |||
| YoY Change | |||
| Treasury Stock (at cost) | |||
| YoY Change | |||
| Treasury Stock Shares | |||
| Shareholders Equity | $397.9M | $494.6M | $487.1M |
| YoY Change | |||
| Total Liabilities & Shareholders Equity | $449.7M | $529.1M | $519.0M |
| YoY Change | -15.01% | 57.47% | 63.63% |
Cashflow Statement
| Concept | 2020 Q2 | 2019 Q2 | 2019 Q1 |
|---|---|---|---|
| OPERATING ACTIVITIES | |||
| Net Income | -$33.76M | -$1.457M | -$32.23M |
| YoY Change | 2217.23% | -113.75% | -130.92% |
| Depreciation, Depletion And Amortization | $2.100M | $1.800M | $1.600M |
| YoY Change | 16.67% | 100.0% | 100.0% |
| Cash From Operating Activities | -$21.50M | -$23.70M | -$29.30M |
| YoY Change | -9.28% | -133.76% | -150.4% |
| INVESTING ACTIVITIES | |||
| Capital Expenditures | -$3.300M | -$5.500M | $2.455M |
| YoY Change | -40.0% | 103.7% | 4.74% |
| Acquisitions | |||
| YoY Change | |||
| Other Investing Activities | $47.80M | $27.20M | $7.900M |
| YoY Change | 75.74% | -176.19% | -122.77% |
| Cash From Investing Activities | $44.50M | $21.60M | $5.461M |
| YoY Change | 106.02% | -156.25% | -114.73% |
| FINANCING ACTIVITIES | |||
| Cash Dividend Paid | |||
| YoY Change | |||
| Common Stock Issuance & Retirement, Net | |||
| YoY Change | |||
| Debt Paid & Issued, Net | |||
| YoY Change | |||
| Cash From Financing Activities | 1.800M | 1.400M | 4.127M |
| YoY Change | 28.57% | -54.84% | -0.94% |
| NET CHANGE | |||
| Cash From Operating Activities | -21.50M | -23.70M | -29.30M |
| Cash From Investing Activities | 44.50M | 21.60M | 5.461M |
| Cash From Financing Activities | 1.800M | 1.400M | 4.127M |
| Net Change In Cash | 24.80M | -700.0K | -19.71M |
| YoY Change | -3642.86% | -102.01% | -178.17% |
| FREE CASH FLOW | |||
| Cash From Operating Activities | -$21.50M | -$23.70M | -$29.30M |
| Capital Expenditures | -$3.300M | -$5.500M | $2.455M |
| Free Cash Flow | -$18.20M | -$18.20M | -$31.75M |
| YoY Change | 0.0% | -124.97% | -156.91% |
Facts In Submission
| Frame | Concept Type | Concept / XBRL Key | Value | Unit |
|---|---|---|---|---|
| CY2019Q2 | us-gaap |
Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
|
-0.04 | |
| us-gaap |
Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
|
-1.98 | ||
| us-gaap |
Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
|
-0.92 | ||
| CY2019Q2 | us-gaap |
Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
|
36669000 | |
| us-gaap |
Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
|
37180000 | ||
| us-gaap |
Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
|
36518000 | ||
| us-gaap |
Profit Loss
ProfitLoss
|
-33685000 | ||
| us-gaap |
Share Based Compensation
ShareBasedCompensation
|
12817000 | ||
| us-gaap |
Depreciation And Amortization
DepreciationAndAmortization
|
4126000 | ||
| rgnx |
Imputed Interest Income From Licensing
ImputedInterestIncomeFromLicensing
|
1375000 | ||
| rgnx |
Increase Decrease In Operating Lease Liabilities
IncreaseDecreaseInOperatingLeaseLiabilities
|
-1171000 | ||
| us-gaap |
Increase Decrease In Other Operating Liabilities
IncreaseDecreaseInOtherOperatingLiabilities
|
-482000 | ||
| us-gaap |
Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
|
-53046000 | ||
| us-gaap |
Payments To Acquire Marketable Securities
PaymentsToAcquireMarketableSecurities
|
106119000 | ||
| us-gaap |
Proceeds From Sale And Maturity Of Marketable Securities
ProceedsFromSaleAndMaturityOfMarketableSecurities
|
141262000 | ||
| us-gaap |
Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
|
27133000 | ||
| CY2020Q2 | us-gaap |
Other Operating Income Expense Net
OtherOperatingIncomeExpenseNet
|
-50000 | |
| CY2020Q2 | us-gaap |
Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
|
-0.91 | |
| rgnx |
Available For Sale Equity Securities Gross Unrealized Gain Loss
AvailableForSaleEquitySecuritiesGrossUnrealizedGainLoss
|
-7779000 | ||
| rgnx |
Available For Sale Equity Securities Gross Unrealized Gain Loss
AvailableForSaleEquitySecuritiesGrossUnrealizedGainLoss
|
31656000 | ||
| rgnx |
Imputed Interest Income From Licensing
ImputedInterestIncomeFromLicensing
|
1900000 | ||
| us-gaap |
Other Noncash Income Expense
OtherNoncashIncomeExpense
|
-373000 | ||
| us-gaap |
Other Noncash Income Expense
OtherNoncashIncomeExpense
|
-442000 | ||
| us-gaap |
Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
|
534000 | ||
| CY2020Q2 | us-gaap |
Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
|
37257000 | |
| CY2020Q1 | us-gaap |
Stockholders Equity
StockholdersEquity
|
420152000 | |
| CY2020Q2 | us-gaap |
Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
|
8316000 | |
| CY2020Q2 | us-gaap |
Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
|
1330000 | |
| CY2020Q2 | us-gaap |
Net Income Loss
NetIncomeLoss
|
-33762000 | |
| CY2020Q2 | us-gaap |
Stockholders Equity
StockholdersEquity
|
397861000 | |
| CY2019Q1 | us-gaap |
Stockholders Equity
StockholdersEquity
|
487053000 | |
| CY2019Q2 | us-gaap |
Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
|
1367000 | |
| CY2019Q2 | us-gaap |
Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
|
7099000 | |
| CY2019Q2 | us-gaap |
Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
|
530000 | |
| CY2019Q2 | us-gaap |
Net Income Loss
NetIncomeLoss
|
-1457000 | |
| CY2019Q2 | us-gaap |
Stockholders Equity
StockholdersEquity
|
494592000 | |
| CY2019Q4 | us-gaap |
Stockholders Equity
StockholdersEquity
|
450197000 | |
| us-gaap |
Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
|
3979000 | ||
| us-gaap |
Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
|
607000 | ||
| us-gaap |
Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
|
16333000 | ||
| us-gaap |
Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
|
545000 | ||
| us-gaap |
Net Income Loss
NetIncomeLoss
|
-73800000 | ||
| CY2020Q2 | us-gaap |
Stockholders Equity
StockholdersEquity
|
397861000 | |
| us-gaap |
Profit Loss
ProfitLoss
|
-73800000 | ||
| us-gaap |
Share Based Compensation
ShareBasedCompensation
|
16333000 | ||
| us-gaap |
Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
|
-205000 | ||
| us-gaap |
Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
|
788000 | ||
| us-gaap |
Depreciation And Amortization
DepreciationAndAmortization
|
3363000 | ||
| us-gaap |
Available For Sale Securities Gross Realized Gain Loss Net
AvailableForSaleSecuritiesGrossRealizedGainLossNet
|
7075000 | ||
| us-gaap |
Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
|
3274000 | ||
| us-gaap |
Increase Decrease In Other Current Assets
IncreaseDecreaseInOtherCurrentAssets
|
3072000 | ||
| us-gaap |
Increase Decrease In Other Current Assets
IncreaseDecreaseInOtherCurrentAssets
|
-1419000 | ||
| rgnx |
Increase Decrease In Operating Lease Right Of Use Assets
IncreaseDecreaseInOperatingLeaseRightOfUseAssets
|
-1443000 | ||
| rgnx |
Increase Decrease In Operating Lease Right Of Use Assets
IncreaseDecreaseInOperatingLeaseRightOfUseAssets
|
-1156000 | ||
| us-gaap |
Increase Decrease In Other Noncurrent Assets
IncreaseDecreaseInOtherNoncurrentAssets
|
-1355000 | ||
| us-gaap |
Increase Decrease In Other Noncurrent Assets
IncreaseDecreaseInOtherNoncurrentAssets
|
1350000 | ||
| us-gaap |
Increase Decrease In Accounts Payable Trade
IncreaseDecreaseInAccountsPayableTrade
|
4078000 | ||
| us-gaap |
Increase Decrease In Accounts Payable Trade
IncreaseDecreaseInAccountsPayableTrade
|
1774000 | ||
| us-gaap |
Increase Decrease In Accrued Liabilities And Other Operating Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
|
1434000 | ||
| us-gaap |
Increase Decrease In Accrued Liabilities And Other Operating Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
|
-957000 | ||
| us-gaap |
Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
|
-600000 | ||
| rgnx |
Increase Decrease In Operating Lease Liabilities
IncreaseDecreaseInOperatingLeaseLiabilities
|
-1197000 | ||
| rgnx |
Additions Related To Accounts Receivable
AdditionsRelatedToAccountsReceivable
|
11049000 | ||
| rgnx |
Deductions Related To Accounts Receivable
DeductionsRelatedToAccountsReceivable
|
-9014000 | ||
| CY2020Q2 | us-gaap |
Debt Securities Available For Sale Allowance For Credit Loss
DebtSecuritiesAvailableForSaleAllowanceForCreditLoss
|
0 | |
| us-gaap |
Increase Decrease In Other Operating Liabilities
IncreaseDecreaseInOtherOperatingLiabilities
|
-1166000 | ||
| us-gaap |
Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
|
-57069000 | ||
| us-gaap |
Payments To Acquire Marketable Securities
PaymentsToAcquireMarketableSecurities
|
70665000 | ||
| us-gaap |
Proceeds From Sale And Maturity Of Marketable Securities
ProceedsFromSaleAndMaturityOfMarketableSecurities
|
146353000 | ||
| rgnx |
Proceeds From Sales Of Marketable Debt Securities
ProceedsFromSalesOfMarketableDebtSecurities
|
2287000 | ||
| us-gaap |
Proceeds From Sale And Maturity Of Available For Sale Securities
ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities
|
7124000 | ||
| us-gaap |
Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
|
7908000 | ||
| us-gaap |
Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
|
8010000 | ||
| us-gaap |
Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
|
77191000 | ||
| us-gaap |
Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
|
3979000 | ||
| us-gaap |
Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
|
5129000 | ||
| us-gaap |
Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans
ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans
|
607000 | ||
| us-gaap |
Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans
ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans
|
365000 | ||
| us-gaap |
Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
|
4586000 | ||
| us-gaap |
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
|
-20419000 | ||
| us-gaap |
Noncash Or Part Noncash Divestiture Amount Of Consideration Received1
NoncashOrPartNoncashDivestitureAmountOfConsiderationReceived1
|
1123000 | ||
| us-gaap |
Nature Of Operations
NatureOfOperations
|
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">1. Nature of Business</p> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">REGENXBIO Inc. (the Company) is a clinical-stage biotechnology company seeking to improve lives through the curative potential of gene therapy. The Company’s proprietary adeno-associated virus (AAV) gene delivery platform (NAV Technology Platform) consists of exclusive rights to over 100 novel AAV vectors, including AAV7, AAV8, AAV9 and AAVrh10. The NAV® Technology Platform is being applied by the Company, as well as by third-party licensees (NAV Technology Licensees), in the development of a broad pipeline of product candidates in multiple therapeutic areas and in one commercially available product, Zolgensma®, which is marketed by a NAV Technology Licensee. The Company was formed in 2008 in the State of Delaware and is headquartered in Rockville, Maryland.</p> <p style="margin-top:18pt;margin-bottom:0pt;margin-left:4.54%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Liquidity and Risks </p> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of June 30, 2020, the Company had generated an accumulated deficit of $251.6 million since inception. As the Company has incurred cumulative losses since inception, transition to recurring profitability is dependent upon achieving a level of revenues adequate to support the Company’s cost structure, which depends heavily on the successful development, approval and commercialization of its product candidates. The Company may never achieve recurring profitability, and unless and until it does, the Company will continue to need to raise additional capital, to the extent possible.<span style="color:#000000;"> As of June 30, 2020, the Company had cash, cash equivalents and marketable securities of $339.2 million, which management believes is sufficient to fund operations for at least the next 12 months from the date these consolidated financial statements were issued.</span></p> <p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company is subject to risks common to companies in the biotechnology industry, including, but not limited to, development by the Company or its competitors of technological innovations, risks of failure of clinical trials, dependence on key personnel, protection of proprietary technology, compliance with government regulations and ability to transition from clinical manufacturing to the commercial production of products.</p> | ||
| CY2020Q2 | us-gaap |
Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
|
-251600000 | |
| CY2020Q2 | us-gaap |
Cash Cash Equivalents And Short Term Investments
CashCashEquivalentsAndShortTermInvestments
|
339200000 | |
| CY2020Q2 | us-gaap |
Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
|
219402000 | |
| CY2020Q2 | us-gaap |
Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
|
25659000 | |
| CY2020Q2 | us-gaap |
Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
|
43000 | |
| CY2020Q2 | us-gaap |
Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
|
245018000 | |
| CY2019Q4 | us-gaap |
Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
|
297631000 | |
| CY2019Q4 | us-gaap |
Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
|
32884000 | |
| CY2019Q4 | us-gaap |
Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
|
34000 | |
| us-gaap |
Use Of Estimates
UseOfEstimates
|
<p style="margin-top:18pt;margin-bottom:0pt;margin-left:4.54%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Use of Estimates</p> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts in the financial statements and accompanying notes. Actual results could differ materially from those estimates. Management considers many factors in selecting appropriate financial accounting policies and controls, and in developing the estimates and assumptions that are used in the preparation of these consolidated financial statements. Management must apply significant judgment in this process. In addition, other factors may affect estimates, including: expected business and operational changes, sensitivity and volatility associated with the assumptions used in developing estimates and whether historical trends are expected to be representative of future trends. The estimation process often may yield a range of potentially reasonable estimates of the ultimate future outcomes and management must select an amount that falls within that range of reasonable estimates. This process </p> <p style="margin-top:6pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">may result in actual results differing materially from those estimated amounts used in the preparation of the consolidated financial statements. Significant estimates are used in the following areas, among others: </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">license and royalty </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">revenue, stock-based compensation expense, accrued research and development expenses and other accrued liabilities, income taxes and the fair value of financial instruments.</span></p> <p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company is actively monitoring the impact of the COVID-19 pandemic on its business, results of operations and financial condition. The full extent to which the COVID-19 pandemic will directly or indirectly impact the Company’s business, results of operations and financial condition in the future is unknown at this time and will depend on future developments that are highly unpredictable. The most significant estimates affecting the Company’s consolidated financial statements that may be impacted by the COVID-19 pandemic are related to the Company’s assessment of credit losses on accounts receivable, contract assets and available-for-sale debt securities.</p> | ||
| us-gaap |
Prior Period Reclassification Adjustment Description
PriorPeriodReclassificationAdjustmentDescription
|
<p style="margin-top:18pt;margin-bottom:0pt;margin-left:4.54%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Reclassifications</p> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Certain amounts reported in prior periods have been reclassified to conform to current period financial statement presentation. These reclassifications are not material and have no effect on previously reported financial position, results of operations and cash flows.</p> | ||
| CY2020Q2 | us-gaap |
Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
|
94222000 | |
| CY2019Q2 | us-gaap |
Restricted Cash And Cash Equivalents Noncurrent
RestrictedCashAndCashEquivalentsNoncurrent
|
1053000 | |
| CY2019Q2 | us-gaap |
Available For Sale Securities Continuous Unrealized Loss Position Less Than Twelve Months Fair Value
AvailableForSaleSecuritiesContinuousUnrealizedLossPositionLessThanTwelveMonthsFairValue
|
61118000 | |
| CY2020Q2 | us-gaap |
Allowance For Doubtful Accounts Receivable
AllowanceForDoubtfulAccountsReceivable
|
0 | |
| CY2019Q4 | us-gaap |
Allowance For Doubtful Accounts Receivable
AllowanceForDoubtfulAccountsReceivable
|
0 | |
| CY2019Q4 | us-gaap |
Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
|
330481000 | |
| CY2020Q2 | rgnx |
Available For Sale Debt Securities Remaining Maturities Greater Than Three Years
AvailableForSaleDebtSecuritiesRemainingMaturitiesGreaterThanThreeYears
|
0 | |
| CY2019Q4 | rgnx |
Available For Sale Debt Securities Remaining Maturities Greater Than Three Years
AvailableForSaleDebtSecuritiesRemainingMaturitiesGreaterThanThreeYears
|
0 | |
| CY2020Q2 | us-gaap |
Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Before Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax
|
-1300000 | |
| us-gaap |
Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Before Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax
|
600000 | ||
| CY2019Q2 | us-gaap |
Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Before Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax
|
800000 | |
| us-gaap |
Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Before Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax
|
1800000 | ||
| CY2020Q2 | us-gaap |
Debt Securities Available For Sale Continuous Unrealized Loss Position Less Than12 Months
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months
|
42913000 | |
| CY2020Q2 | us-gaap |
Debt Securities Available For Sale Continuous Unrealized Loss Position Less Than12 Months Accumulated Loss
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss
|
43000 | |
| CY2020Q2 | us-gaap |
Debt Securities Available For Sale Unrealized Loss Position
DebtSecuritiesAvailableForSaleUnrealizedLossPosition
|
42913000 | |
| CY2020Q2 | us-gaap |
Debt Securities Available For Sale Unrealized Loss Position Accumulated Loss
DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss
|
43000 | |
| CY2020Q2 | rgnx |
Additions Related To Accounts Receivable
AdditionsRelatedToAccountsReceivable
|
18834000 | |
| CY2020Q2 | rgnx |
Deductions Related To Accounts Receivable
DeductionsRelatedToAccountsReceivable
|
-21235000 | |
| CY2019Q2 | us-gaap |
Debt Securities Available For Sale Continuous Unrealized Loss Position Less Than12 Months Accumulated Loss
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss
|
34000 | |
| CY2019Q2 | us-gaap |
Available For Sale Securities Continuous Unrealized Loss Position Fair Value
AvailableForSaleSecuritiesContinuousUnrealizedLossPositionFairValue
|
61118000 | |
| CY2019Q2 | us-gaap |
Debt Securities Available For Sale Unrealized Loss Position Accumulated Loss
DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss
|
34000 | |
| CY2020Q2 | us-gaap |
Debt Securities Available For Sale Unrealized Loss Position Number Of Positions
DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions
|
11 | |
| us-gaap |
Other Than Temporary Impairment Loss Debt Securities Available For Sale
OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSale
|
0 | ||
| CY2020Q2 | rgnx |
Non Marketable Equity Securities
NonMarketableEquitySecurities
|
400000 | |
| CY2020Q2 | us-gaap |
Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
|
245018000 | |
| CY2019Q4 | us-gaap |
Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
|
330481000 | |
| CY2020Q2 | rgnx |
Non Marketable Equity Securities Carrying Value
NonMarketableEquitySecuritiesCarryingValue
|
1100000 | |
| CY2019Q4 | rgnx |
Non Marketable Equity Securities Carrying Value
NonMarketableEquitySecuritiesCarryingValue
|
0 | |
| CY2020Q2 | rgnx |
Remeasurements Or Impairment Losses On Non Marketable Equity Securities
RemeasurementsOrImpairmentLossesOnNonMarketableEquitySecurities
|
0 | |
| CY2019Q2 | rgnx |
Remeasurements Or Impairment Losses On Non Marketable Equity Securities
RemeasurementsOrImpairmentLossesOnNonMarketableEquitySecurities
|
0 | |
| rgnx |
Remeasurements Or Impairment Losses On Non Marketable Equity Securities
RemeasurementsOrImpairmentLossesOnNonMarketableEquitySecurities
|
0 | ||
| rgnx |
Remeasurements Or Impairment Losses On Non Marketable Equity Securities
RemeasurementsOrImpairmentLossesOnNonMarketableEquitySecurities
|
0 | ||
| CY2020Q2 | us-gaap |
Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
|
51124000 | |
| CY2019Q4 | us-gaap |
Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
|
43311000 | |
| CY2020Q2 | us-gaap |
Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
|
18428000 | |
| CY2019Q4 | us-gaap |
Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
|
14338000 | |
| CY2020Q2 | us-gaap |
Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
|
32696000 | |
| CY2019Q4 | us-gaap |
Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
|
28973000 | |
| rgnx |
Milestone Fee Payments Upon Submission Preclinical Filings
MilestoneFeePaymentsUponSubmissionPreclinicalFilings
|
300000 | ||
| rgnx |
Milestone Fee Payments Upon Commencement Of Clinical Trials
MilestoneFeePaymentsUponCommencementOfClinicalTrials
|
26600000 | ||
| rgnx |
Milestone Fee Payments Upon Submission Of Regulatory Approval Filings
MilestoneFeePaymentsUponSubmissionOfRegulatoryApprovalFilings
|
26000000.0 | ||
| rgnx |
Milestone Fee Payments Upon Approval Of Commercial Products
MilestoneFeePaymentsUponApprovalOfCommercialProducts
|
103500000 | ||
| rgnx |
Milestone Fee Payments Upon Achievement Of Specified Sales Targets
MilestoneFeePaymentsUponAchievementOfSpecifiedSalesTargets
|
137000000.0 | ||
| CY2020Q1 | us-gaap |
Accounts Receivable Net
AccountsReceivableNet
|
48895000 | |
| CY2019Q1 | us-gaap |
Accounts Receivable Net
AccountsReceivableNet
|
31130000 | |
| CY2019Q4 | us-gaap |
Accounts Receivable Net
AccountsReceivableNet
|
42300000 | |
| rgnx |
Additions Related To Contract With Customer Liability
AdditionsRelatedToContractWithCustomerLiability
|
1124000 | ||
| CY2020Q2 | us-gaap |
Contract With Customer Liability
ContractWithCustomerLiability
|
4457000 | |
| CY2020Q1 | us-gaap |
Contract With Customer Asset Net Current
ContractWithCustomerAssetNetCurrent
|
350000 | |
| CY2020Q1 | us-gaap |
Contract With Customer Liability
ContractWithCustomerLiability
|
3333000 | |
| CY2020Q2 | rgnx |
Additions Related To Contract With Customer Liability
AdditionsRelatedToContractWithCustomerLiability
|
1124000 | |
| CY2020Q2 | us-gaap |
Contract With Customer Liability
ContractWithCustomerLiability
|
4457000 | |
| CY2019Q4 | us-gaap |
Accounts Receivable Net
AccountsReceivableNet
|
42303000 | |
| rgnx |
Additions Related To Accounts Receivable
AdditionsRelatedToAccountsReceivable
|
36976000 | ||
| rgnx |
Deductions Related To Accounts Receivable
DeductionsRelatedToAccountsReceivable
|
-32785000 | ||
| CY2020Q2 | us-gaap |
Accounts Receivable Net
AccountsReceivableNet
|
46494000 | |
| rgnx |
Additions Related To Contract With Customer Assets
AdditionsRelatedToContractWithCustomerAssets
|
350000 | ||
| CY2020Q2 | us-gaap |
Contract With Customer Asset Net Current
ContractWithCustomerAssetNetCurrent
|
350000 | |
| CY2019Q4 | us-gaap |
Contract With Customer Liability
ContractWithCustomerLiability
|
3333000 | |
| CY2019Q2 | rgnx |
Additions Related To Accounts Receivable
AdditionsRelatedToAccountsReceivable
|
9312000 | |
| CY2019Q2 | rgnx |
Deductions Related To Accounts Receivable
DeductionsRelatedToAccountsReceivable
|
-6808000 | |
| CY2019Q1 | us-gaap |
Contract With Customer Asset Net Current
ContractWithCustomerAssetNetCurrent
|
1000000 | |
| CY2019Q2 | rgnx |
Deductions Related To Contract With Customer Asset
DeductionsRelatedToContractWithCustomerAsset
|
-1000000 | |
| CY2019Q1 | us-gaap |
Contract With Customer Liability
ContractWithCustomerLiability
|
3933000 | |
| CY2019Q2 | rgnx |
Deductions Related To Contract With Customer Liability
DeductionsRelatedToContractWithCustomerLiability
|
-600000 | |
| CY2019Q2 | us-gaap |
Contract With Customer Liability
ContractWithCustomerLiability
|
3333000 | |
| CY2018Q4 | us-gaap |
Accounts Receivable Net
AccountsReceivableNet
|
31599000 | |
| CY2019Q2 | us-gaap |
Accounts Receivable Net
AccountsReceivableNet
|
33634000 | |
| CY2018Q4 | us-gaap |
Contract With Customer Asset Net Current
ContractWithCustomerAssetNetCurrent
|
750000 | |
| rgnx |
Additions Related To Contract With Customer Assets
AdditionsRelatedToContractWithCustomerAssets
|
1000000 | ||
| rgnx |
Deductions Related To Contract With Customer Asset
DeductionsRelatedToContractWithCustomerAsset
|
-1750000 | ||
| CY2018Q4 | us-gaap |
Contract With Customer Liability
ContractWithCustomerLiability
|
3933000 | |
| rgnx |
Deductions Related To Contract With Customer Liability
DeductionsRelatedToContractWithCustomerLiability
|
-600000 | ||
| CY2019Q2 | us-gaap |
Contract With Customer Liability
ContractWithCustomerLiability
|
3333000 | |
| CY2020Q2 | us-gaap |
Contract With Customer Liability
ContractWithCustomerLiability
|
4500000 | |
| CY2020Q2 | us-gaap |
Accounts Receivable Net
AccountsReceivableNet
|
46500000 | |
| CY2020Q2 | us-gaap |
Billed Contract Receivables
BilledContractReceivables
|
30000000.0 | |
| CY2020Q2 | us-gaap |
Unbilled Contracts Receivable
UnbilledContractsReceivable
|
16500000 | |
| CY2019Q4 | us-gaap |
Billed Contract Receivables
BilledContractReceivables
|
400000 | |
| CY2019Q4 | us-gaap |
Unbilled Contracts Receivable
UnbilledContractsReceivable
|
41900000 | |
| rgnx |
Capitalized Contract Cost Credit Loss
CapitalizedContractCostCreditLoss
|
0 | ||
| CY2020Q2 | rgnx |
Capitalized Contract Cost Credit Loss
CapitalizedContractCostCreditLoss
|
0 | |
| CY2020Q2 | us-gaap |
Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
|
15445000 | |
| CY2019Q2 | us-gaap |
Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
|
4424000 | |
| us-gaap |
Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
|
25424000 | ||
| us-gaap |
Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
|
4424000 | ||
| CY2020Q2 | us-gaap |
Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
|
8316000 | |
| CY2019Q2 | us-gaap |
Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
|
7099000 | |
| us-gaap |
Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
|
16333000 | ||
| us-gaap |
Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
|
12817000 | ||
| rgnx |
Proceeds From Stock Options Exercised Including Unsettled Options
ProceedsFromStockOptionsExercisedIncludingUnsettledOptions
|
4000000.0 | ||
| rgnx |
Cares Act Of2020 Elimination Of Net Operating Loss Deductions As Percentage Of Taxable Income
CARESActOf2020EliminationOfNetOperatingLossDeductionsAsPercentageOfTaxableIncome
|
0.80 | ||
| rgnx |
Recovery Period Of Property Under Tax Cuts And Jobs Act
RecoveryPeriodOfPropertyUnderTaxCutsAndJobsAct
|
P15Y | ||
| us-gaap |
Current Income Tax Expense Benefit
CurrentIncomeTaxExpenseBenefit
|
-500000 | ||
| CY2020Q2 | us-gaap |
Current Income Tax Expense Benefit
CurrentIncomeTaxExpenseBenefit
|
-500000 | |
| us-gaap |
Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
|
6534000 | ||
| CY2020Q2 | us-gaap |
Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
|
6534000 | |
| us-gaap |
Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
|
5520000 | ||
| CY2019Q2 | us-gaap |
Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
|
5520000 | |
| CY2020Q2 | us-gaap |
Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
|
9356000 | |
| CY2019Q4 | us-gaap |
Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
|
10903000 | |
| CY2020Q2 | rgnx |
Accrued External Research And Development Expenses
AccruedExternalResearchAndDevelopmentExpenses
|
6832000 | |
| CY2019Q4 | rgnx |
Accrued External Research And Development Expenses
AccruedExternalResearchAndDevelopmentExpenses
|
5791000 | |
| CY2020Q2 | rgnx |
Accrued Sublicense Fees And Royalties On Reagent Sales
AccruedSublicenseFeesAndRoyaltiesOnReagentSales
|
6602000 | |
| CY2019Q4 | rgnx |
Accrued Sublicense Fees And Royalties On Reagent Sales
AccruedSublicenseFeesAndRoyaltiesOnReagentSales
|
4542000 | |
| CY2020Q2 | rgnx |
Accrued External General And Administrative Expenses
AccruedExternalGeneralAndAdministrativeExpenses
|
2069000 | |
| CY2019Q4 | rgnx |
Accrued External General And Administrative Expenses
AccruedExternalGeneralAndAdministrativeExpenses
|
2053000 | |
| CY2020Q2 | rgnx |
Accrued Purchases Of Property And Equipment
AccruedPurchasesOfPropertyAndEquipment
|
887000 | |
| CY2019Q4 | rgnx |
Accrued Purchases Of Property And Equipment
AccruedPurchasesOfPropertyAndEquipment
|
1328000 | |
| CY2020Q2 | us-gaap |
Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
|
93000 | |
| CY2019Q4 | us-gaap |
Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
|
229000 | |
| CY2020Q2 | rgnx |
Accrued Expenses And Other Current Liabilities
AccruedExpensesAndOtherCurrentLiabilities
|
25839000 | |
| CY2019Q4 | rgnx |
Accrued Expenses And Other Current Liabilities
AccruedExpensesAndOtherCurrentLiabilities
|
24846000 |
